Two-year cumulative incidence of transplantation-related mortality (TRM), relapse (RI), and probability of leukemia-free survival (LFS) in 266 patients with AML and ALL receiving a haplo-HSCT according to disease status
| . | TRM (%) . | RI (%) . | LFS (%) . | |||
|---|---|---|---|---|---|---|
| AML . | ALL . | AML . | ALL . | AML . | ALL . | |
| CR1 | 36 ± 10 | 61 ± 10 | 16 ± 10 | 26 ± 9 | 48 ± 10 | 13 ± 7 |
| CR2 | 54 ± 5 | 44 ± 9 | 23 ± 5 | 27 ± 8 | 21 ± 5 | 30 ± 8 |
| Advanced | 66 ± 4 | 44 ± 9 | 32 ± 1 | 49 ± 9 | 1 ± 1 | 7 ± 5 |
| . | TRM (%) . | RI (%) . | LFS (%) . | |||
|---|---|---|---|---|---|---|
| AML . | ALL . | AML . | ALL . | AML . | ALL . | |
| CR1 | 36 ± 10 | 61 ± 10 | 16 ± 10 | 26 ± 9 | 48 ± 10 | 13 ± 7 |
| CR2 | 54 ± 5 | 44 ± 9 | 23 ± 5 | 27 ± 8 | 21 ± 5 | 30 ± 8 |
| Advanced | 66 ± 4 | 44 ± 9 | 32 ± 1 | 49 ± 9 | 1 ± 1 | 7 ± 5 |